KIT D816V–mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression-Reference-Cited by-同舟云学术

KIT D816V–mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression

Published:2016-02-11 Issue:6 Volume:127 Page:761-768
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Garcia-Montero Andres C.¹,Jara-Acevedo Maria²,Alvarez-Twose Ivan³,Teodosio Cristina⁴,Sanchez-Muñoz Laura³,Muñiz Carmen¹,Muñoz-Gonzalez Javier I.¹,Mayado Andrea¹,Matito Almudena³,Caldas Carolina¹,Morgado Jose M.³,Escribano Luis¹,Orfao Alberto¹

Affiliation:

1. Servicio General de Citometría (NUCLEUS) and

2. Servicio de Secuenciación de ADN, Centro de Investigación del Cáncer (Instituto de Biología Molecular y Celular del Cancer–Consejo Superior de Investigaciones Científicas [IBMCC-CSIC]/Universidad de Salamanca [USAL] and Institute of Biomedical Research of Salamanca [IBSAL]) and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain;

3. Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain; and

4. Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

Abstract

Key Points Acquisition of the KIT D816V mutation in an early pluripotent progenitor cell confers ISM cases a greater risk for disease progression. Despite the early acquisition of the KIT mutation, onset of clinical symptoms of ISM is often delayed to middle adulthood.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/127/6/761/1394077/761.pdf

Reference64 articles.

1. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.;Nagata;Proc Natl Acad Sci USA,1995

2. Recent advances in the understanding of mastocytosis: the role of KIT mutations.;Orfao;Br J Haematol,2007

3. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis.;Arock;Leukemia,2015

4. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.;Garcia-Montero;Blood,2006

5. Mastocytosis: molecular mechanisms and clinical disease heterogeneity.;Metcalfe;Leuk Res,2001

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Indolent systemic mastocytosis and aleukemic mast cell leukemia: Subtle diagnostic differences with distinct management approaches;JAAD Case Reports;2023-06

2. New Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy;Annual Review of Pathology: Mechanisms of Disease;2023-01-24

3. KIT D816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes;Allergy;2022-11-28

4. Avapritinib for the treatment of KIT mutation–negative systemic mastocytosis;Baylor University Medical Center Proceedings;2022-09-20

5. Remission of indolent systemic mastocytosis in the absence of targeted therapy;The Journal of Allergy and Clinical Immunology: In Practice;2022-08